ABBVAbbVieRunning, no new patients
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom Macroglobulinemia · Lymphoplasmacytic Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 14 (planned)
- Started
- Mar 17, 2026
- Main results expected
- Jul 2028
- Fully finished
- Jul 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Major Response
Measured over: Up to Approximately 28 Months
Number of Participants with Major Response in participants with IgM >= 500 mg/dL
Measured over: Up to Approximately 28 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07387471 · record last updated 2026-09-09 · checked 2026-11-09 15:47 UTC